Schizophrenia Clinical Trials

81 studies are recruiting for schizophrenia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. 52-week Open Label Safety-Tolerability Study

   Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Chandler Clinical Trials, Chandler, Arizona

   Locations

   23 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07369154 on ClinicalTrials.gov

2. Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

   Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher poten…

   Stage

   Phase 1

   Ages

   21 to 60

   Site

   West Haven Veterans Affairs Medical Center, West Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT06058702 on ClinicalTrials.gov

3. A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

   A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Collaborative Neuroscience Research, LLC, Los Alamitos, California

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07061288 on ClinicalTrials.gov

4. Cerebellar Modulation of Cognition in Psychosis

   The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Pa…

   Stage

   Not phased

   Ages

   18 to 55

   Site

   McLean Hospital, Belmont, Massachusetts

   Locations

   2 in total

   Run by

   Mclean Hospital

   See if you can join NCT06107764 on ClinicalTrials.gov

5. Enhancing Veteran-Clinical Collaboration in VA PRRCs

   Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives. Although traditional treatments tend to focus on symptom remission, Veterans prioritize a range of treatment goals, including…

   Stage

   Not phased

   Ages

   18 and older

   Site

   New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico

   Locations

   3 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT06898879 on ClinicalTrials.gov

6. REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)

   The purpose of this study is to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions. The investigators are especially interested in learning whether the Clubhouse Mo…

   Stage

   Not phased

   Ages

   18 to 50

   Site

   Case Western Reserve University, Cleveland, Ohio

   Run by

   Case Western Reserve University

   See if you can join NCT07006935 on ClinicalTrials.gov

7. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

   To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

   Stage

   Phase 3

   Ages

   10 to 17

   Site

   Alkermes Investigator Site, Dothan, Alabama

   Locations

   47 in total

   Run by

   Alkermes, Inc.

   See if you can join NCT05303064 on ClinicalTrials.gov

8. Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

   This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

   Stage

   Phase 1

   Ages

   10 to 17

   Site

   BioXcel Clinical Research Site, Anaheim, California

   Locations

   5 in total

   Run by

   BioXcel Therapeutics Inc

   See if you can join NCT05025605 on ClinicalTrials.gov

9. Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

   This study will investigate the effects of intermittent Theta Burst Stimulation (iTBS) on natural oscillatory frequency of the dorsolateral prefrontal cortex (DLPFC) and working memory in early-course schizophrenia (EC-SCZ). Transcranial magnetic stimulation (TMS) will be used to evoke oscillatory …

   Stage

   Not phased

   Ages

   18 to 40

   Site

   University of Pittsburgh, Pittsburgh, Pennsylvania

   Run by

   Fabio Ferrarelli

   See if you can join NCT05102929 on ClinicalTrials.gov

10. Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode

    The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other …

    Stage

    Not phased

    Ages

    18 to 45

    Site

    UCLA Aftercare Research Program, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT05890183 on ClinicalTrials.gov

11. Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

    The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Pillar Clinical Research LLC, Bentonville, Arkansas

    Locations

    16 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT07467993 on ClinicalTrials.gov

12. Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

    This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Pillar Clinical Research, Bentonville, Arkansas

    Locations

    13 in total

    Run by

    LB Pharmaceuticals Inc.

    See if you can join NCT07363577 on ClinicalTrials.gov

13. Tolerability of MDMA in Schizophrenia

    Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness. Whereas many symptoms of schizophrenia can be treated with antipsychotic medications, deficits in social motivation persist, leading to signific…

    Stage

    Phase 1

    Ages

    18 to 60

    Site

    UCLA, Los Angeles, California

    Run by

    Anya Bershad, MD, PhD

    See if you can join NCT05770375 on ClinicalTrials.gov

14. Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental Illness

    The proposed research will test the hypothesis that objective social isolation and loneliness are linked to neurobehavioral mechanisms involved in social perception and motivation in individuals with and without serious mental illness. Moreover, it will investigate the specific dynamic interactions…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    Massachusetts General Hospital, Charlestown, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT04940663 on ClinicalTrials.gov

15. Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

    Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Acacia Clinics, Sunnyvale, California

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT06376734 on ClinicalTrials.gov

16. Anticholinergic Deprescription in Schizophrenia

    In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unnee…

    Stage

    Phase 4

    Ages

    40 to 70

    Site

    UPMC Western Psychiatric Hospital/University of Pittsburgh, Pittsburgh, Pennsylvania

    Run by

    Deepak K. Sarpal, M.D.

    See if you can join NCT06562608 on ClinicalTrials.gov

17. Acetazolamide for Treatment Resistant Schizophrenia

    This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    University of Pittsburgh, Pittsburgh, Pennsylvania

    Locations

    2 in total

    Run by

    Vishwajit Nimgaonkar, MD PhD

    See if you can join NCT04887792 on ClinicalTrials.gov

18. Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)

    Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.

    Stage

    Not phased

    Ages

    18 to 60

    Site

    The University of Texas Health Science Center, Houston, Houston, Texas

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT06345963 on ClinicalTrials.gov

19. Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)

    Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil combined with cognitive training for improving white matter integrity.

    Stage

    Not phased

    Ages

    18 to 60

    Site

    The University of Texas Health Science Center, Houston, Houston, Texas

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT06961916 on ClinicalTrials.gov

20. Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness

    This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI). The two-arm randomized controlled trial will compare the efficacy of YE compared to the Wellness Lifestyle Program (WLP). Prima…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania

    Run by

    VA Office of Research and Development

    See if you can join NCT05157620 on ClinicalTrials.gov

21. Restoring Spindle and Thalamocortical Efficiency in Early-Course Schizophrenia Patients Using Auditory Stimulation

    The purpose of this research is to identify differences in brain activity during sleep between health individuals and individuals with schizophrenia, schizophreniform, or schizoaffective disorder. This study will also investigate whether tones played during deep sleep can enhance specific features …

    Stage

    Not phased

    Ages

    18 to 40

    Site

    University of Pittsburgh, Pittsburgh, Pennsylvania

    Run by

    Fabio Ferrarelli

    See if you can join NCT05956951 on ClinicalTrials.gov

22. Anti-Inflammatory Challenge in Schizophrenia

    This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain circuits. The primary goal of this study is to determine: * Ventral St…

    Stage

    Phase 4

    Ages

    18 to 55

    Site

    Grady Memorial Hospital, Atlanta, Georgia

    Locations

    2 in total

    Run by

    Emory University

    See if you can join NCT05823532 on ClinicalTrials.gov

23. Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia

    The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitan…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Vanderbilt Psychiatric Hospital, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT07196462 on ClinicalTrials.gov

24. Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

    The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated levels of sugar and bad cholesterol. Participants will be randomly assigned to either take lumateperone …

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    UMass Chan Medical School, Worcester, Massachusetts

    Run by

    University of Massachusetts, Worcester

    See if you can join NCT06174116 on ClinicalTrials.gov

25. CLOZAPINE Response in Biotype-1

    The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as ps…

    Stage

    Phase 4

    Ages

    18 to 60

    Site

    Hartford Healthcare, Hartford, Connecticut

    Locations

    5 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04580134 on ClinicalTrials.gov